Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01DA032533-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of South Carolina | OTHER |
| Michigan State University | OTHER |
| University of Miami | OTHER |
| University of Massachusetts, Worcester |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Many individuals with schizophrenia also suffer from marijuana addiction that worsens their problems related to schizophrenia. Most of the medications prescribed for schizophrenia have no effect on reducing marijuana use. Preliminary data suggests that clozapine, an atypical antipsychotic, may limit marijuana use in people diagnosed with schizophrenia, but it is not commonly used due to its side effects and is reserved for people who do not respond to other antipsychotic medications.
In the proposed study, 132 individuals who are diagnosed with both schizophrenia and a cannabis use disorder will be randomized to a 12-week treatment course with either clozapine or risperidone (another commonly prescribed antipsychotic medication) to test the hypothesis that patient treated with clozapine will have decreased cannabis use as compared to patients treated with risperidone.
Should this study indicate that clozapine will lessen marijuana use in persons diagnosed with schizophrenia more than risperidone, it will provide evidence needed to begin to shift clinical practice toward its use in this population.
Cannabis use disorder (CUD), which is up to ten times more common in patients with schizophrenia (SCZ) than in the general population, worsens the course of this severe psychiatric disorder. Since SCZ occurs in 1% of the population, the co-occurrence of CUD in 13% to 42% of people with this disorder presents society with an important public health problem. Unfortunately, most antipsychotics available for treatment of patients with SCZ do not appear to limit their cannabis use. Moreover, the one antipsychotic that preliminary data suggest may well limit cannabis use in these patients, clozapine (CLOZ), is not used for this purpose; it is reserved for patients whose psychosis is treatment resistant.
The overarching idea behind this proposal, however, is that CLOZ's use is being unreasonably restricted and should be made more widely available for patients with SCZ who have a co-occurring CUD but whose psychosis is not necessarily treatment resistant. This notion is supported by our preliminary clinical and animal data on the effects of CLOZ, as well as our neurobiological model of the basis of cannabis use in patients with SCZ that provides a pharmacologic rationale for this effect of CLOZ.
Even given all the arguments favoring the potential benefits of CLOZ in patients with SCZ and CUD, however, its side effect profile will likely limit its use until a fully powered study demonstrates its ability to decrease cannabis use in patients with SCZ. This proposal aims to launch such a study. If, as we hypothesize, this study confirms and extends our previous preliminary data of the effects of CLOZ in patients with SCZ and CUD, it will provide a strong impetus to expand the use of CLOZ in this population.
In the proposed study, 132 patients who are comorbid for both SCZ and CUD will be randomized to a 12-week treatment course with either CLOZ or risperidone (RISP) to test the hypothesis that patients treated with CLOZ will have decreased cannabis use as compared to patients treated with RISP. In addition, the study will determine whether patients treated with CLOZ will have improvements in psychiatric symptoms, quality of life neuropsychological functions as compared to those taking RISP. We will also explore whether patients taking CLOZ show improved reward responsiveness as compared to those taking RISP. Finally, this study will explore whether those patients with the val/val genotype at the Catechol-O-methyltransferase (COMT) Val158Met locus are more likely to decrease cannabis use during CLOZ treatment than are those without the val/val COMT genotype.
Should this study indicate that CLOZ will lessen cannabis use in patients with SCZ more than RISP, it will provide evidence needed to begin to shift clinical practice toward its use in these patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clozapine | Experimental | The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day. |
|
| Risperidone | Active Comparator | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clozapine | Drug | Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) | Intensity of cannabis use is obtained each week retrospectively as the number of joints smoked during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. | 12 weeks |
| Average Over Time of Frequency of Cannabis Use | Frequency of cannabis use is obtained each week retrospectively as the number of days of cannabis use during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. | 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alan I Green, MD | Dartmouth College | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CNS Network Inc | Garden Grove | California | 92845 | United States | ||
| Pacific Research Partners |
During the course of the study a pharmacy issue precipitated the need to conduct the study as open label for a period of time. 7 participants (5 CLOZ and 2 RISP) were randomized under open label. Once a replacement pharmacy was in place the study returned to double blind status.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Clozapine | The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day. Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day |
| FG001 | Risperidone | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion. Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Two subjects and their data were excluded from the study due to unreliability (1 CLOZ, 1 RISP).
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Clozapine | The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day. Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) | Intensity of cannabis use is obtained each week retrospectively as the number of joints smoked during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. | Average number of joints Over Time was calculated using the midpoint of 6.5 weeks. NOTE: Outlying data for a CLOZ and RISP subject were removed from the analyses . Additionally, two subjects were excluded from the study due to unreliability (1 CLOZ, 1 RISP). | Posted | Number | 95% Confidence Interval | joints smoked during the prior week | 12 weeks |
|
6 months
Two subjects and their data were excluded from the study due to unreliability (1 CLOZ, 1 RISP).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Clozapine | The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day. Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Psychosis | Psychiatric disorders | Systematic Assessment | Psychosis |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Leukopenia | Blood and lymphatic system disorders | Systematic Assessment | Leukopenia |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Mary Brunette | Psychopharmacology Research Group | 603-271-5054 | mary.f.brunette@hitchcock.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 15, 2016 | Oct 25, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D003024 | Clozapine |
| D018967 | Risperidone |
| ID | Term |
|---|---|
| D003984 | Dibenzazepines |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| Risperidone | Drug | Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day |
|
|
| Oakland |
| California |
| 94607 |
| United States |
| University of Miami | Miami | Florida | 33136 | United States |
| Unversity of Massachusetts Medical School | Worcester | Massachusetts | 01605 | United States |
| Michigan State University / Cherry Street Health Services | Grand Rapids | Michigan | 49503 | United States |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | United States |
| University of North Carolina/UNC Center for Excellence in Community Mental Health | Raleigh | North Carolina | 27610 | United States |
| University of South Carolina | Columbia | South Carolina | 29203 | United States |
| Rutland Regional Medical Center | Rutland | Vermont | 05701 | United States |
| BG001 | Risperidone | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion. Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Clozapine |
The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day. Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day |
| OG001 | Risperidone | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion. Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day |
|
|
|
| Primary | Average Over Time of Frequency of Cannabis Use | Frequency of cannabis use is obtained each week retrospectively as the number of days of cannabis use during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. | Average number of days of cannabis use over time was calculated using the midpoint 6.5 weeks. NOTE: Outlying data for a CLOZ and RISP subject were removed from the analyses. Additionally, two subjects and their data were excluded from the study due to unreliability (1 CLOZ, 1 RISP). | Posted | Number | 95% Confidence Interval | days of cannabis use during prior week | 12 weeks |
|
|
|
|
| 0 |
| 23 |
| 3 |
| 23 |
| 23 |
| 23 |
| EG001 | Risperidone | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion. Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day | 0 | 24 | 3 | 24 | 21 | 24 |
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment | Abdominal pain |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment | Dyspnea |
|
| other-rhabdomyolisis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Suicidal ideation | Psychiatric disorders | Systematic Assessment | Suicidal ideation |
|
| Tachycardia | Cardiac disorders | Systematic Assessment | Tachycardia |
|
| Abdominal pain | Gastrointestinal disorders | Abdominal pain | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment | Constipation |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| other-Sialorrhea | Gastrointestinal disorders | Systematic Assessment | other-Sialorrhea |
|
| hypercholesterolemia | Metabolism and nutrition disorders | Systematic Assessment | hypercholesterolemia |
|
| Hyperglycemia | Metabolism and nutrition disorders | Systematic Assessment | Hyperglycemia |
|
| Hypertriglyceridemia | Metabolism and nutrition disorders | Systematic Assessment | Hypertriglyceridemia |
|
| Increased appetite | Metabolism and nutrition disorders | Systematic Assessment | Increased appetite |
|
| weight gain | Metabolism and nutrition disorders | Systematic Assessment | weight gain |
|
| Back Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment | Back pain |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment | Cough |
|
| Dizziness | Nervous system disorders | Systematic Assessment | Dizziness |
|
| Extrpyramidal Effects | Nervous system disorders | Systematic Assessment | Extrapyramidal Effects |
|
| Headache | Nervous system disorders | Systematic Assessment | Headache |
|
| Insomnia | Nervous system disorders | Systematic Assessment |
|
| Sedation | Psychiatric disorders | Systematic Assessment | Sedation |
|
| Suicidal Ideation | Psychiatric disorders | Systematic Assessment | Suicidal Ideation |
|
| Tremor | Nervous system disorders | Systematic Assessment | Tremor |
|
Not provided
Not provided
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |